CSE CEO: Psychedelics Investing is a Pharma Play

TL;DR

The Canadian Securities Exchange (CSE) has extended its support from the cannabis industry to companies involved in the psychedelic space, helping them raise growth capital in the public equity markets.

Transcript

for the investing news network i am brian mcgovern i'm joined today by richard carlson the ceo of the canadian securities exchange richard thank you so much for your time my pleasure brian thank you richard we're going to be talking a little bit about psychedelics investments today and how quickly that market has changed in canada and overall first... Read More

Key Insights

• 🤨 The CSE has extended its support from the cannabis industry to the psychedelics sector, helping companies raise growth capital in the public equity markets.
• 🍉 Psychedelics differ from cannabis in terms of market dynamics and investment opportunities, with psychedelics being more focused on pharmaceutical applications.
• 💨 The FDA has shown positive signs by granting fast track approvals for some psychedelic research companies, indicating the potential for these compounds to become accepted treatments.
• 👨‍🔬 Research conducted on psychedelics in the 1950s and early 60s showed promising results, providing additional support for the current research being conducted in the field.
• 👨‍🔬 Investing in the psychedelics sector requires an understanding of the long-term nature of drug development, as it involves extensive research, clinical trials, and FDA approvals.
• 👨‍🔬 The psychedelics market offers different investment opportunities, including research-based companies, addiction treatment facilities, and wellness-focused ventures.
• 👂 Before listing on the CSE, companies must provide positive statements and legal opinions supporting their business activities in jurisdictions where they operate.

Questions & Answers

Q: What has been the CSE's involvement with the cannabis industry?

The CSE has supported the cannabis industry in Canada, the United States, and globally, with a significant percentage of its issuers and market capitalization being in the cannabis space.

Q: How did companies in the psychedelic space face similar challenges to early cannabis companies?

Companies in the psychedelic space also struggled to attract investment from conventional sources and turned to the public equity markets, seeking growth capital. They faced regulatory and disclosure issues similar to those of cannabis companies.

Q: What are the differences between the cannabis and psychedelics markets in terms of investment opportunities?

The cannabis market is a consumer package goods opportunity with a known addressable market. Psychedelics, on the other hand, are more focused on pharmaceutical applications and require extensive research, clinical trials, and FDA approvals.

Q: What signs indicate that the psychedelic sector is heading in the right direction for investment opportunities?

Some early research companies in the psychedelics space have received fast track approvals from the FDA to advance to the next phase of clinical trials. This indicates promising preliminary results and the potential for these compounds to become mainstream treatments.

Summary & Key Takeaways

• The CSE has been involved in supporting the cannabis industry in Canada, the United States, and globally.

• Companies in the psychedelic space faced similar challenges to early cannabis companies and turned to public equity markets for growth capital.

• The CSE provided guidance to these companies on disclosure issues and helped them navigate the regulatory landscape.